



Suggested Formula	Cefixime 100 mg /5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 006 077
-------------------	--	-----	-----------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Cefixime (Trihydrate), USP	TBD					
Stevia Powder	0.30	g				
Strawberry Flavor	1.0	mL				
Glycerin, USP	2.0	mL				
Medisca Oral Suspend (Suspending Vehicle)	45.0	mL				
Medisca Oral Syrup (Flavored Vehicle)	q.s. to 100.0	mL				

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Hygroscopic (protect from moisture whenever possible): Cefixime, Glycerin, Stevia Powder

Light Sensitive (protect from light whenever possible): Cefixime

Suggested Preparatory Guidelines

Non-Sterile Preparation Sterile Preparation

Processing Error / Testing Considerations: To account for processing error considerations during preparation, it is suggested to measure an additional **5 to 9%** of the required quantities of ingredients.

Special Instruction: Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.
This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Cefixime 100 mg /5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 006 077
-------------------	--	-----	-----------

SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor ^(*) : _____	Processing Error	Qty. to measure
Cefixime (Trihydrate), USP §	TBD				
Stevia Powder §	0.30	g			
Strawberry Flavor	1.0	mL			
Glycerin, USP §	2.0	mL			
Medisca Oral Suspend (Suspending Vehicle)	45.0	mL			
Medisca Oral Syrup (Flavored Vehicle)	q.s. to 100.0	mL			

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

Preparatory Instruction

1. Ingredient quantification:

A. Determine the potency of Cefixime (Trihydrate) based on the certificate of analysis:

MINUS	100%
Water Content (from certificate of analysis)	_____ %
DIVIDED BY	100
EQUALS	
Quantity of water free Cefixime (Trihydrate), in decimal	_____
MULTIPLY BY	
Assay on anhydrous basis result (from certificate of analysis)	_____ µg/mg
MULTIPLY BY (Multiplication factor – µg to grams /mg to grams)	0.001
EQUALS	
i. Potency of Cefixime (anhydrous basis) in g/g	_____



Suggested Formula	Cefixime 100 mg /5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 006 077
-------------------	--	-----	-----------

2. **Ingredient quantification:**

- A. Determine the quantity (in g) of Cefixime (Trihydrate) required to make a 100 mL batch of Cefixime (anhydrous basis) 100 mg/5 mL Oral Liquid:

Quantity of Cefixime (anhydrous basis) required for 100 mL	2.000 g
DIVIDED BY	
Potency of Cefixime (anhydrous basis) in g/g (Step 1Ai)	_____
EQUALS	
i. Quantity of Cefixime (Trihydrate) needed for 100 mL	_____ g
MULTIPLIED BY	
Processing error adjustments (5 to 9%)	1.05 to 1.09
EQUALS	
ii. Quantity of Cefixime (Trihydrate) needed <i>plus</i> processing error adjustments	_____ g

3. **Powder-liquid preparation:**

- A. Combine and triturate the following ingredients together to form a fine, homogeneous powder blend:

- Cefixime (Trihydrate) (amount determined in Step 2Aii)
- Stevia Powder

- B. Combine and mix the following ingredients together to form a homogeneous liquid-like solution:

- Glycerin
- Strawberry Flavor

- C. Levigate the fine, homogeneous powder blend (Step 3A) with the homogeneous liquid-like solution (Step 3B).

End result: Homogeneous liquid-like dispersion.



Suggested Formula	Cefixime 100 mg /5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 006 077
-------------------	--	-----	-----------

4.	<p><u>Medium incorporation:</u></p> <p>A. Incrementally add the homogenous liquid-like dispersion (Step 3C) to the Oral Suspend (Suspending Vehicle).</p> <p><u>Specifications:</u> Continuously mix, using high-shear mixing techniques.</p> <p><u>End result:</u> Homogeneous liquid-like dispersion.</p>
5.	<p><u>Filling to volume:</u></p> <p>A. Add Oral Syrup (Flavored Vehicle) to the mixture (Step 4A) to fill to the required batch size (100.0 mL <i>plus</i> processing error adjustments).</p> <p><u>Specifications:</u> Continuously mix, using high-shear mixing techniques.</p> <p><u>End result:</u> Homogeneous liquid-like dispersion.</p>
6.	<p><u>Product transfer:</u></p> <p>A. Transfer the final product into the specified dispensing container (see “Packaging requirements”).</p>

SUGGESTED PRESENTATION

Estimated Beyond-Use Date	14 days, refrigerated, as per USP.	Packaging Requirements	- Tightly closed, light-resistant dispensing bottle. - To be administered with a metered-dose measuring device.	
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	5	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.
	2	Protect from light.	6	Keep out of reach of children.
	3	Keep refrigerated. Do not freeze.	7	Cap tightly after use.
	4	Shake well before use.		
Pharmacist Instructions	Add any auxiliary labels specific to the active ingredients to the dispensing container as deemed necessary.			
Patient Instructions	Contact your pharmacist in the event of adverse reactions.			



Suggested Formula	Cefixime 100 mg /5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 006 077
-------------------	--	-----	-----------

REFERENCES

1.	Suspensions. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Third Edition</i> . American Pharmaceutical Association; 2008: 209.
2.	Suprax. In: <i>Physicians Desk Reference</i> ®. Montvale, NJ: Thomson PDR; 2009: 1891.
3.	Glycerin. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 6th Edition</i> . American Pharmaceutical Association; 2009: 283.
4.	Cefixime. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition</i> . London, England: The Pharmaceutical Press; 2009: 224.
5.	Cefixime (Monograph). In: O'Neil MJ. <i>The Merck Index 14th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2006: Monograph #1924.
6.	Cefixime (Monograph). <i>United States Pharmacopeia XXXVII / National Formulary 32</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2014: 2203.
7.	Cefixime. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26th Edition</i> . Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 833.
8.	USP <795>. <i>United States Pharmacopeia XXXVII / National Formulary 32</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2014: 403.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.